Treatment-Responsive Subacute Limbic Encephalitis and NMDA Receptor Antibodies in a Man
Neurol 70:728-729, Novillo-Lopez,M.E.,et al, 2008
The Writing on the Wall
Lancet 372:344, Wilder-Smith,E.P. &Ng,E.S., 2008
Response of Anti-NMDA Receptor Encephalitis Without Tumor to Immunotherapy Including Rituximab
Neurol 71:1921-1923, Ishiura,H.,et al, 2008
Limbic Encephalitis and Variants: Classification, Diagnosis and Treatment
Neurologist 13:261-271, Tuzun,E. &Dalmau,J., 2007
A 24-Week Open-Label Extension Study of Memantine in Moderate to Severe Alzheimer Disease
Arch Neurol 63:49-54, Reisberg,B.,et al, 2006
A Case of Voltage-Gated Potassium Channel Antibody-Related Limbic Encephalitis
Nat Clin Pract Neurol 2:339-343, Harrower,T., et al, 2006
Voltage-Gated Potassium Channel Antibody-Associated Encephalitis with Basal Ganglia Lesions
Neurol 66:1780-1781, Hiraga,A., et al, 2006
Survival after Treatment of Rabies with Induction of Coma
NEJM 352:2508-2514,2549, Willoughby,Jr.,R.E.,et al, 2005
Treatment-Responsive Limbic Encephalitis Identified by Neuropil Antibodies: MRI and PET Correlates
Brain 128:1764-1777, Ances,B.M., et al, 2005
Memantine Treatment in Patients with Moderate to Severe Alzheimer Disease Already Receiving Donepezil, A Randomized Controlled Trial
JAMA 291:317-324, Tariot,P.N.,et al, 2004
Potassium Channel Antibody-Associated Encephalopathy: A Potentially Immunotherapy-Responsive Form of Limbic Encepahlitis
Brain 127:701-712, Vincent,A.,et al, 2004
Potentially Reversible Autoimmune Limbic ncephalitis with Neuronal Potassium Channel Antibody
Neurol 62:1177-1182,1040, Thieben,M.J.,et al, 2004
Voltage-Gated Potassium Channel Antibodies in Limbic Encephalitis
Ann Neurol 54:530-533, Pozo-Rosich,P.,et al, 2003
Amnesia, Cerebral Atrophy, and Autoimmunity
Lancet 361:1266, Schott,J.M., et al, 2003
Memantine in Moderate-to-Severe Alzheimer's Disease
NEJM 348:1333-1341, Reisberg,B.,et al, 2003
Tolerability of Memantine in Combination with Cholinesterase Inhibitors in Dementia Therapy
Int Clin Psychopharm 18:81-85, Hartmann,S.& Mobius, H.J., 2003
Acute Leukoencephalopathies:Differential Diagnosis and Investigation
The Neurologist 4:148-166, Weinshenker,B.G.,et al, 1998
Progression of Ischaemic Stroke and Excitotoxic Aminoacids
Lancet 349:79-83, Castillo,J.,et al, 1997
Clinical Experience with Excitatory Amino Acid Antagonist Drugs
Stroke 26:503-513, Muir,K.W.&Lees,K.R., 1995
The Ischemic Penumbra, Injury Thresholds, and the Therapeutic Window for Acute Stroke
Ann Neurol 36:553-554, 5571994., Ginsberg,M.D.&Pulsinelli,W.A., 1994
Prophylactic Neuroprotection for Cerebral Ischemia
Stroke 25:1075-1080, Fisher,M.,et al, 1994
Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders
NEJM 330:613-622, Lipton,S.A.&Rosenberg,P.A., 1994
A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis
NEJM 330:585-591, Bensimon,G.,et al, 1994
Evolving Toward Effective Therapy for Acute Ischemic Stroke
JAMA 270:360-364, Fisher,M.&Bogousslavsky,J., 1993
Do NMDA Antagonists Prevent Neuronal Injury? Yes
ARch Neurol 49:418-420, Albers,G.W.,et al, 1992
Do NMDA Antagonists Prevent Neuronal Injury? No
Arch Neurol 49:420-421, Buchan,A.M., 1992
N-Methyl-D-Aspartate Antagonists in the Treatment of Parkinson's Disease
Arch Neurol 48:977-981, Greenamyre,J.T.&O'Brien,C.F., 1991
Tissue Plasminogen Activator Plus Glutamate Antagonist Improves Outcome after Embolic Stroke
Arch Neurol 48:1235-1238, Zivin,J.A.&Mazzarella,V., 1991
The Bioloigcal Basis for the Treatment of Acute Stroke
Neurol 41:1867-1873, Scheinberg,P., 1991
A Teenager with Chronic Meningitis-Does Occams Razor Apply?
Neurol 100:828-835, Havuluri,H.,et al, 2023
Glucose Hypermetabolism in the Basal Ganglia
Neurol 101:90-91, Kim,Y.E.,et al, 2023
Clinicopathologic Conference, Diffuse Large B-Cell Lymphoma
NEJM 386:977-986, Case 7-2022, 2022
Toward Simpler, Safer Treatment of Cryptococcal Meningitis
NEJM 386:1179-1181, Moosa, M.Y.S. & Lessells, R.J., 2022
A 56-Year-Old Man with Unusual Presentation of Subacute Encephalopathy and Seizure
Neurol 98:e95-e102, Wang, T.,et al, 2022
Clinicopathologic Conference, Anti-IgLON5 IgG-Associated Neurologic Disorder
NEJM 386:173-180, Case 1-2022, 2022
Dura Mater Thickening and Enhancement in Anti-NMDAR Encephalitis
Neurol 99:628-629, Xia, C. & Chen, H.S., 2022
Atypical Unilateral Cortical Ribboning in Anti-NMDA Receptor Encephalitis
Neurol 99:1062-1063, Chen,A.Y.,et al, 2022
Thymoma and Autoimmune Encephalitis
Neuroimmunol Neuroinflamm 8:e1053, Guasp,M.,et al, 2021
Autoimmune Encephalitis Related to Cancer Treatment with Immune Checkpoint Inhibitors
Neurol 97:e191-e202, Nersesjan, V.,et al, 2021
A 68-Year-Old Man with Proximal Weakness and Seizures
Neurol 97:e423-e428, Chen, T., 2021
Pembrolizumab-Induced Migrating Cortico-Subcortical Brain Lesions
Ann Neurol 89:1255-1256, Lambert, N.,et al, 2021
Encephalitis Induced by Immune Checkpoint Inhibitors
JAMA Neurol 78:864-873, Velasco, R.,et al, 2021
CASPR2 Autoimmunity in Children Expanding to Mild Encephalopathy with Hypertension
Neurol 94:e2290-e2301,953, Syrbe, S.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
An Adolescent Girl Presenting with Worsening Vertigo, Headache, and Ataxia
Neurol 95:e1760-e1763, Brigham, E.,et al, 2020
Clinicopathologic conference, Cryptococcal meningoencephalitis and advanced HIV infection
NEJM 383:2572-2580, Case 40-2020, 2020
Myasthenia Gravis Following Dabrafenib and Trametinib for Metastatic Melanoma
Neurol 94:322-323, Zaloum, A.,et al, 2020
Immunocompetent Patient with Multiple Cranial Nerve Palsies, Ataxia, and Cognitive Decline
Neurol 94:e225-e229, Nigam, M.,et al, 2020
Management and Outcome of Primary CNS Lymphoma in the Modern Era
Neurol 94:e1027-e1039, Houillier, C., et al, 2020
Anti-NMDAR Encephalitis with Overlapping Demyelinating Syndrome
Neurol 94:e1866-e1869, Kim, H.W., et al, 2020